Maintained renin-angiotensin-aldosterone system inhibitor therapy with sodium zirconium cyclosilicate following a hyperkalaemia episode: a multicountry cohort study

By sjmartinez • May 3, 2024

Rastogi A, Pollack CV Jr, Sánchez Lázaro IJ, Lesén E, Arnold M, Franzén S, Allum A, Hernández I, Murohara T, Kanda E. Maintained renin-angiotensin-aldosterone system inhibitor therapy with sodium zirconium cyclosilicate following a hyperkalaemia episode: a multicountry cohort study. Clin Kidney J. 2024 Mar 25;17(5):sfae083. doi: 10.1093/ckj/sfae083. PMID: 38699484; PMCID: PMC11062025.

Tags: Chronic kidney disease, heart failure, hyperkalaemia, Nephrology, Publications, renin–angiotensin–aldosterone system inhibitor, sodium zirconium cyclosilicate

Incidence of chronic kidney disease among adults with prediabetes in the CURE-CKD registry, 2013-2020

Alicic RZ, Duru OK, Jones CR, Kornowske LM, Daratha KB, Reynolds CL, Pavkov ME, Koyama AK, Xu F, Nicholas SB, Neumiller JJ, Norris KC, Hennessey[...]

Expert Discussion on Immune Complex-Mediated Membranoproliferative Glomerulonephritis: Challenges and Considerations

Lafayette RA, Charu V, Glassock RJ. Expert Discussion on Immune Complex-Mediated Membranoproliferative Glomerulonephritis: Challenges and Considerations. Adv Ther. 2025 Mar 27. doi: 10.1007/s12325-025-03167-x. Epub ahead[...]

The End Kidney Deaths Act Risks Irreversible Harm to Organ Donation

Mueller TF, Matamoros MA, Danovitch GM, Nagral S. The End Kidney Deaths Act Risks Irreversible Harm to Organ Donation. JAMA. 2025 Mar 26. doi: 10.1001/jama.2025.2409.[...]